Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Van Stijn, Caroline M W ^a   Kim, Jason ^a   Barish, Grant D ^b   Tietge, Uwe J F ^c   Tangirala, Rajendra K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ADIPONECTIN; ANGIOTENSIN II; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; SCAVENGER RECEPTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; HEART PROTECTION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WESTERN BLOTTING;

ADIPONECTIN; ANGIOTENSIN II; ANIMALS; APOLIPOPROTEINS; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HYPERTENSION; INFLAMMATION; LIVER; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; RECEPTORS, ADIPONECTIN; RECEPTORS, LDL; RECEPTORS, SCAVENGER;

EID: 84899657349     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086404     Document Type: Article

References (63)

1. Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11: 85-97.
2. Scherer PE (2006) Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55: 1537-1545.
3. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
4. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793-1801. (Pubitemid 44033299)
5. Berg AH, Scherer PE (2005) Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96: 939-949. (Pubitemid 40712793)
6. Shetty S, Kusminski CM, Scherer PE (2009) Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 30: 234-239.
7. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, et al. (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221: 286-289. (Pubitemid 26136463)
8. Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697-10703. (Pubitemid 26145805)
9. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749.
10. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152-12162. (Pubitemid 38445780)
11. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, et al. (2003) Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278: 40352-40363. (Pubitemid 37248604)
12. Ouchi N, Shibata R, Walsh K (2006) Cardioprotection by adiponectin. Trends Cardiovasc Med 16: 141-146. (Pubitemid 43867326)
13. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784-1792. (Pubitemid 44033298)
14. Kazumi T, Kawaguchi A, Hirano T, Yoshino G (2004) Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 53: 589-593. (Pubitemid 38596530)
15. Weiss R, Otvos JD, Flyvbjerg A, Miserez AR, Frystyk J, et al. (2009) Adiponectin and lipoprotein particle size. Diabetes Care 32: 1317-1319.
16. Yamauchi T, Kadowaki T (2013) Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 17: 185-196.
17. Unger T (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89: 3A-9A; discussion 10A.
18. Brasier AR, Recinos A 3rd, Eledrisi MS (2002) Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22: 1257-1266. (Pubitemid 34875734)
19. Daugherty A, Cassis L (2004) Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 14: 117-120. (Pubitemid 38569679)
20. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA (2004) Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110: 3849-3857. (Pubitemid 40023984)
21. Hattori Y, Akimoto K, Gross SS, Hattori S, Kasai K (2005) Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 48: 1066-1074. (Pubitemid 40909640)
22. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, et al. (2006) Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55: 478-488.
23. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, et al. (2003) Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16: 72-75. (Pubitemid 36078595)
24. Ohashi K, Ouchi N, Matsuzawa Y (2011) Adiponectin and hypertension. Am J Hypertens 24: 263-269.
25. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, et al. (2007) Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 49: 1455-1461. (Pubitemid 46809394)
26. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, et al. (2006) Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47: 1108-1116. (Pubitemid 44289168)
27. Watanabe S, Okura T, Kurata M, Irita J, Manabe S, et al. (2006) The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther 28: 1677-1685. (Pubitemid 44848364)
28. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, et al. (2003) Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42: 76-81. (Pubitemid 36842239)
29. Uchida T, Shimizu M, Sakai Y, Nakano T, Hara K, et al. (2008) Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. Metabolism 57: 1278-1285.
30. Yamauchi T, Kadowaki T (2008) Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 32 Suppl 7: S13-18.
31. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, et al. (2004) Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94: e27-31.
32. Lin LY, Lin CY, Su TC, Liau CS (2004) Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Lett 574: 106-110.
33. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, et al. (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100: 2473-2476. (Pubitemid 30005109)
34. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, et al. (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057-1063. (Pubitemid 32200177)
35. Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, et al. (2007) Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 117: 1718-1726. (Pubitemid 46871356)
36. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, et al. (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106: 2767-2770. (Pubitemid 35396973)
37. Nawrocki AR, Hofmann SM, Teupser D, Basford JE, Durand JL, et al. (2010) Lack of association between adiponectin levels and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 30: 1159-1165.
38. Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, et al. (2008) PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A 105: 4277-4282. (Pubitemid 351754371)
39. Tangirala RK, Rubin EM, Palinski W (1995) Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 36: 2320-2328.
40. Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, et al. (2002) Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A 99: 11896-11901. (Pubitemid 34994495)
41. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, et al. (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125: 1905-1919.
42. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD (2012) High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 32: 2813-2820.
43. Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, et al. (2007) Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 358: 1091-1095. (Pubitemid 46829000)
44. Takata Y, Chu V, Collins AR, Lyon CJ, Wang W, et al. (2005) Transcriptional repression of ATP-binding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II. Circ Res 97: e88-96.
45. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, et al. (1999) Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100: 1816-1822. (Pubitemid 29498389)
46. Tsukamoto K, Smith P, Glick JM, Rader DJ (1997) Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. J Clin Invest 100: 107-114. (Pubitemid 27311248)
47. Fisher FM, Trujillo ME, Hanif W, Barnett AH, McTernan PG, et al. (2005) Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 48: 1084-1087. (Pubitemid 40909642)
48. Oku H, Matsuura F, Koseki M, Sandoval JC, Yuasa-Kawase M, et al. (2007) Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 581: 5029-5033. (Pubitemid 47576080)
49. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, et al. (2005) Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115: 1333-1342. (Pubitemid 40629053)
50. Qiao L, Zou C, van der Westhuyzen DR, Shao J (2008) Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 57: 1824-1833.
51. Neumeier M, Sigruener A, Eggenhofer E, Weigert J, Weiss TS, et al. (2007) High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochem Biophys Res Commun 352: 543-548. (Pubitemid 44838520)
52. Basso F, Amar MJ, Wagner EM, Vaisman B, Paigen B, et al. (2006) Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet. Biochem Biophys Res Commun 351: 398-404. (Pubitemid 44679753)
53. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, et al. (2008) Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 102: 218-225. (Pubitemid 351651126)
54. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, et al. (2000) An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32: 47-50. (Pubitemid 30143606)
55. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, et al. (2001) PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7: 53-58. (Pubitemid 32095642)
56. Daynes RA, Jones DC (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2: 748-759. (Pubitemid 37328715)
57. O'Neill LA, Hardie DG (2013) Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493: 346-355.
58. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, et al. (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102: 1296-1301.
59. Salminen A, Hyttinen JM, Kaarniranta K (2011) AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 89: 667-676.
60. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, et al. (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13: 332-339. (Pubitemid 46376688)
61. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, et al. (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17: 55-63.
62. Matavelli LC, Huang J, Siragy HM (2011) Angiotensin AT(2) receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 57: 308-313.
63. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, et al. (2010) Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 285: 6153-6160.